Artificial Intelligence in Diabetes Care
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70720 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Michal Dubský und 5 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Hauptthemen laut MEDLINE: Artificial Intelligence, Diabetes Mellitus, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Institute for Research on Metabolic and Cardiovascular Diseases, European Union Next-Generation EU.
Themen: Künstliche Intelligenz in der Pflege, Diabetes mellitus
Abstract (Originalsprache)
Background
Diabetes care requires frequent and high‐stakes decisions that must be made in the setting of substantial day‐to‐day physiologic variability. The growing availability of continuous glucose monitoring, connected insulin delivery devices and longitudinal electronic health record data has created an opportunity for algorithm‐enabled tools that can synthesise high‐frequency data, reduce cognitive burden for patients and clinicians, and support safer and more consistent decision‐making.
Aim
In this review, artificial intelligence (AI) is used broadly to describe computational systems that generate predictions, recommendations or automation from clinical data.
Methods
We distinguish between algorithmic automation and control methods that underpin many currently deployed automated insulin delivery (AID) systems and machine learning–based models, including deep learning and large language models (LLMs), that are increasingly used for pattern recognition, risk prediction and natural language applications.
Results
This distinction is clinically relevant because evidence standards, safety risks and governance needs vary substantially across these categories.
Conclusion
This narrative review summarises current and emerging applications of AI in diabetes care with an emphasis on clinical readiness, strength of evidence and implementation considerations. We highlight established applications in AID, emerging approaches that seek greater autonomy and interoperability and newer tools such as LLMs, wearables and digital twin frameworks, focusing on where evidence is strongest, where risks are highest and what safeguards are required for responsible clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- First Faculty of Medicine, Charles University, Prague, Czech Republic.
- Faculty of Science, Jan Evangelista Purkyně University, Ústí nad Labem, Czech Republic.
- Second Faculty of Medicine, Charles University, Prague, Czech Republic.
- Diabetes Center, Tameside and Glossop Integrated Care NHS Foundation Trust and University of Manchester, Ashton-under-Lyne, Lancashire, UK.
ORCID-Profile: Michal Dubský, Edward B Jude
Förderung
- National Institute for Research on Metabolic and Cardiovascular Diseases
- European Union Next-Generation EU
Zitieren
APA
Dubský, M., Liegertová, M., Bém, R., Sojáková, D., Fejfarová, V., & Jude, E. B. (2026). Artificial Intelligence in Diabetes Care. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70720
Vancouver
Dubský M, Liegertová M, Bém R, Sojáková D, Fejfarová V, Jude EB. Artificial Intelligence in Diabetes Care. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70720
BibTeX
@article{Dubsk2026,
author = {Dubský, Michal and Liegertová, Michaela and Bém, Robert and Sojáková, Dominika and Fejfarová, Vladimíra and Jude, Edward B},
title = {Artificial Intelligence in Diabetes Care},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70720}
}
EUVIMED